Literature DB >> 25253341

Variation of the specificity of the human antibody responses after tick-borne encephalitis virus infection and vaccination.

Johanna Jarmer1, Jürgen Zlatkovic1, Georgios Tsouchnikas1, Oksana Vratskikh1, Judith Strauß1, Judith H Aberle1, Vaclav Chmelik2, Michael Kundi3, Karin Stiasny1, Franz X Heinz4.   

Abstract

UNLABELLED: Tick-borne encephalitis (TBE) virus is an important human-pathogenic flavivirus endemic in large parts of Europe and Central and Eastern Asia. Neutralizing antibodies specific for the viral envelope protein E are believed to mediate long-lasting protection after natural infection and vaccination. To study the specificity and individual variation of human antibody responses, we developed immunoassays with recombinant antigens representing viral surface protein domains and domain combinations. These allowed us to dissect and quantify antibody populations of different fine specificities in sera of TBE patients and vaccinees. Postinfection and postvaccination sera both displayed strong individual variation of antibody titers as well as the relative proportions of antibodies to different domains of E, indicating that the immunodominance patterns observed were strongly influenced by individual-specific factors. The contributions of these antibody populations to virus neutralization were quantified by serum depletion analyses and revealed a significantly biased pattern. Antibodies to domain III, in contrast to what was found in mouse immunization studies with TBE and other flaviviruses, did not play any role in the human neutralizing antibody response, which was dominated by antibodies to domains I and II. Importantly, most of the neutralizing activity could be depleted from sera by a dimeric soluble form of the E protein, which is the building block of the icosahedral herringbone-like shell of flaviviruses, suggesting that antibodies to more complex quaternary epitopes involving residues from adjacent dimers play only a minor role in the total response to natural infection and vaccination in humans. IMPORTANCE: Tick-borne encephalitis (TBE) virus is a close relative of yellow fever, dengue, Japanese encephalitis, and West Nile viruses and distributed in large parts of Europe and Central and Eastern Asia. Antibodies to the viral envelope protein E prevent viral attachment and entry into cells and thus mediate virus neutralization and protection from disease. However, the fine specificity and individual variation of neutralizing antibody responses are currently not known. We have therefore developed new in vitro assays for dissecting the antibody populations present in blood serum and determining their contribution to virus neutralization. In our analysis of human postinfection and postvaccination sera, we found an extensive variation of the antibody populations present in sera, indicating substantial influences of individual-specific factors that control the specificity of the antibody response. Our study provides new insights into the immune response to an important human pathogen that is of relevance for the design of novel vaccines.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25253341      PMCID: PMC4248988          DOI: 10.1128/JVI.02086-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  73 in total

1.  Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus.

Authors:  Sigrid Elshuber; Steven L Allison; Franz X Heinz; Christian W Mandl
Journal:  J Gen Virol       Date:  2003-01       Impact factor: 3.891

Review 2.  Affinity-based selection and the germinal center response.

Authors:  Tyani D Chan; Robert Brink
Journal:  Immunol Rev       Date:  2012-05       Impact factor: 12.988

3.  Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice.

Authors:  Juergen Zlatkovic; Karin Stiasny; Franz X Heinz
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

4.  Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody.

Authors:  Joseph J B Cockburn; M Erika Navarro Sanchez; Nickolas Fretes; Agathe Urvoas; Isabelle Staropoli; Carlos M Kikuti; Lark L Coffey; Fernando Arenzana Seisdedos; Hugues Bedouelle; Felix A Rey
Journal:  Structure       Date:  2012-01-26       Impact factor: 5.006

5.  Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition.

Authors:  Kimberly A Dowd; Swati Mukherjee; Richard J Kuhn; Theodore C Pierson
Journal:  J Virol       Date:  2014-07-30       Impact factor: 5.103

6.  Homogeneity of the structural glycoprotein from European isolates of tick-borne encephalitis virus: comparison with other flaviviruses.

Authors:  F X Heinz; C Kunz
Journal:  J Gen Virol       Date:  1981-12       Impact factor: 3.891

Review 7.  Antibody-mediated neutralization of flaviviruses: a reductionist view.

Authors:  Kimberly A Dowd; Theodore C Pierson
Journal:  Virology       Date:  2011-01-20       Impact factor: 3.616

8.  Capturing a virus while it catches its breath.

Authors:  Theodore C Pierson; Richard J Kuhn
Journal:  Structure       Date:  2012-02-08       Impact factor: 5.006

9.  A new mechanism for the neutralization of enveloped viruses by antiviral antibody.

Authors:  S W Gollins; J S Porterfield
Journal:  Nature       Date:  1986 May 15-21       Impact factor: 49.962

10.  The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.

Authors:  Laura A VanBlargan; Swati Mukherjee; Kimberly A Dowd; Anna P Durbin; Stephen S Whitehead; Theodore C Pierson
Journal:  PLoS Pathog       Date:  2013-12-05       Impact factor: 6.823

View more
  36 in total

Review 1.  Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

Authors:  Laura A VanBlargan; Leslie Goo; Theodore C Pierson
Journal:  Microbiol Mol Biol Rev       Date:  2016-10-26       Impact factor: 11.056

2.  Molecular Basis of a Protective/Neutralizing Monoclonal Antibody Targeting Envelope Proteins of both Tick-Borne Encephalitis Virus and Louping Ill Virus.

Authors:  Xu Yang; Jianxun Qi; Ruchao Peng; Lianpan Dai; Ernest A Gould; George F Gao; Po Tien
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

Review 3.  Subdominance in Antibody Responses: Implications for Vaccine Development.

Authors:  Gunnar Lindahl
Journal:  Microbiol Mol Biol Rev       Date:  2020-11-25       Impact factor: 11.056

4.  Structural Basis of Zika Virus-Specific Antibody Protection.

Authors:  Haiyan Zhao; Estefania Fernandez; Kimberly A Dowd; Scott D Speer; Derek J Platt; Matthew J Gorman; Jennifer Govero; Christopher A Nelson; Theodore C Pierson; Michael S Diamond; Daved H Fremont
Journal:  Cell       Date:  2016-07-27       Impact factor: 41.582

5.  Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific.

Authors:  Tina M Cairns; Zhen-Yu Huang; John R Gallagher; Yixin Lin; Huan Lou; J Charles Whitbeck; Anna Wald; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2015-06-24       Impact factor: 5.103

Review 6.  Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host.

Authors:  Richard J Kuhn; Kimberly A Dowd; Carol Beth Post; Theodore C Pierson
Journal:  Virology       Date:  2015-03-30       Impact factor: 3.616

Review 7.  Prospects for a Zika Virus Vaccine.

Authors:  Dan H Barouch; Stephen J Thomas; Nelson L Michael
Journal:  Immunity       Date:  2017-02-21       Impact factor: 31.745

Review 8.  The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis.

Authors:  Franz X Heinz; Karin Stiasny
Journal:  Microbiol Mol Biol Rev       Date:  2017-02-08       Impact factor: 11.056

Review 9.  Zika Virus: Immunity and Vaccine Development.

Authors:  Theodore C Pierson; Barney S Graham
Journal:  Cell       Date:  2016-09-29       Impact factor: 41.582

10.  Structural basis of potent Zika-dengue virus antibody cross-neutralization.

Authors:  Giovanna Barba-Spaeth; Wanwisa Dejnirattisai; Alexander Rouvinski; Marie-Christine Vaney; Iris Medits; Arvind Sharma; Etienne Simon-Lorière; Anavaj Sakuntabhai; Van-Mai Cao-Lormeau; Ahmed Haouz; Patrick England; Karin Stiasny; Juthathip Mongkolsapaya; Franz X Heinz; Gavin R Screaton; Félix A Rey
Journal:  Nature       Date:  2016-06-23       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.